Stephen Squinto, Life Sciences Private Capital chief investment officer
November 1, 2022 10:51 AM EDTUpdated 02:17 PM
Deals
Bioregnum

JP Mor­gan splash­es in­to the life sci­ences, tap­ping Stephen Squin­to to run ven­ture team with high-pow­ered ad­vi­sors

This morn­ing we’re get­ting an­oth­er clear sign of just how much pri­vate eq­ui­ty has come to love bio­phar­ma dur­ing these stress­ful post-boom times and bat­tered …

Endpoints Premium

This article is available only to Premium subscribers

Upgrade to Premium for unlimited access and Premium exclusives.

UPGRADE
TRENDING NOW

Up­dat­ed: Trump ad­min­is­tra­tion re­veals 'most fa­vored na­tion' drug price coun­try tar­gets

In his first ma­jor pol­i­cy roll­out, Vinay Prasad looks to chal­lenge ex­ist­ing 'dog­ma' on Covid vac­cines

Up­dat­ed: FDA ad­comm splits votes on Genen­tech and J&J can­cer drugs

Makary, Prasad spell out FDA ground rules for fu­ture Covid vac­cine ap­provals

RFK Jr. spars with sen­a­tors over re­search cuts, HHS bud­get plan

sponsored

Does your sup­ply chain hold up un­der pres­sure for high-risk tem­per­a­ture-crit­i­cal ship­ments?

A service from the Financial Times